Suggested remit: To appraise the clinical and cost effectiveness of risankizumab within its marketing authorisation for treating previously treated moderately to severely active Crohn’s disease.
Status In progress
Technology type Medicine
Decision Selected
Process STA
ID number 3986

Provisional Schedule

Committee meeting: 1 13 December 2022
Expected publication 08 March 2023

Project Team

Project lead Thomas Feist

Email enquiries


Key events during the development of the guidance:

Date Update
22 April 2022 Invitation to participate
28 January 2022 - 25 February 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
24 November 2021 In progress. DHSC referral received

For further information on our processes and methods, please see our CHTE processes and methods manual